Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study

Proteasome (PIs) and hystone deacetylase inhibitors (HDACis) have previously shown synergistic activity in the treatment of relapesed/refractory multiple myeloma (RRMM) patients. In this phase 1 study, we combined carfilzomib, a second generation PI, with panobinostat, a HDACi, to determine the maxi...

詳細記述

保存先:
書誌詳細
出版年:Blood Cancer J
主要な著者: Kaufman, Jonathan L., Mina, Roberto, Jakubowiak, Andrzej J., Zimmerman, Todd L., Wolf, Jeffrey J., Lewis, Colleen, Gleason, Charise, Sharp, Cathy, Martin, Thomas, Heffner, Leonard T., Nooka, Ajay K., Harvey, R. Donald, Lonial, Sagar
フォーマット: Artigo
言語:Inglês
出版事項: Nature Publishing Group UK 2019
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6320362/
https://ncbi.nlm.nih.gov/pubmed/30610196
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-018-0154-8
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料